Hedge Fund Stock Picks & Ticker Coverage
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Harding Loevner Global Equity Harding Loevner LP | “Neurocrine Biosciences ($NBIX), representing 0.8% of the fund's portfolio, is a commercial-stage biopharmaceutical enterprise focused on discovering and developing therapies for neurological, neuroendocrine, and neuropsychiatric disorders. The manager initiated a position as an attractive quality-growth alternative to Vertex, viewing Neurocrine as successfully diversifying beyond its flagship commercial asset. Economically, the company possesses a strong economic moat anchored by its proprietary franchise Ingrezza for tardive dyskinesia, paired with its newly launched treatment Crenessity for congenital adrenal hyperplasia. At approximately 20 times estimated 2026 earnings, compared to higher-multiple biotechnology peers, the stock's valuation offers an attractive entry multiple with modest pipeline expectations embedded in the valuation. Near-term catalysts include commercial uptake and reimbursement coverage for Crenessity, alongside ongoing label expansion for Ingrezza. Key downside risks include integration and clinical development execution risks surrounding its $3 billion acquisition of Soleno Therapeutics, as well as regulatory and reimbursement pricing pressures.” | BULL | Q3 2026 Oct 14, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.